Mouse anti-Human GARS Monoclonal Antibody | anti-GARS antibody

GARS Antibody

Cat. Num. AAA9216863

• Gene Names: GARS; HMN5; CMT2D; DSMAV; GlyRS; SMAD1
• Reactivity: Human
• Applications: Western Blot
• Synonyms: GARS; Monoclonal Antibody; GARS Antibody; Purified Mouse Monoclonal Antibody (Mab); Glycine--tRNA ligase; 6.1.1.14; Diadenosine tetraphosphate synthetase; AP-4-A synthetase; Glycyl-tRNA synthetase; GlyRS; anti-GARS antibody

• Host: Mouse
• Reactivity: Human
• Clonality: Monoclonal
• Sequence Length: 685

• Applicable Applications for anti-GARS antibody: Western Blot (WB)
• Application Notes: WB~~1:4000
• Antigen Type: Recombinant Protein
• Preparation and Storage: Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C in small aliquots to prevent freeze-thaw cycles.

Western Blot (WB)

(All lanes : Anti-GARS Antibody at 1:4000 dilutionLane 1: HT-1080 whole cell lysateLane 2: Jurkat whole cell lysateLane 3: Ramos whole cell lysateLysates/proteins at 20 ug per lane. SecondaryGoat Anti-mouse IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 83 kDaBlocking/Dilution buffer: 5% NFDM/TBST.)

Related Product Information for anti-GARS antibody

Catalyzes the attachment of glycine to tRNA(Gly). Is also able produce diadenosine tetraphosphate (Ap4A), a universal pleiotropic signaling molecule needed for cell regulation pathways, by direct condensation of 2 ATPs.

Product Categories/Family for anti-GARS antibody

Crown Antibodies

References

Shiba K.,et al.J. Biol. Chem. 269:30049-30055(1994). Williams J.H.,et al.Nucleic Acids Res. 23:1307-1310(1995). Ota T.,et al.Nat. Genet. 36:40-45(2004). Hillier L.W.,et al.Nature 424:157-164(2003). Ge Q.,et al.J. Biol. Chem. 269:28790-28797(1994).

NCBI and Uniprot Product Information

• NCBI GI #: 943350815
• NCBI GeneID: 2617
• NCBI Accession #: NP_001303701.1
• NCBI GenBank Nucleotide #: NM_001316772.1
• UniProt Accession #: P41250; Q969Y1; B3KQA2; B4DIA0
• Molecular Weight: 83,166 Da
• NCBI Official Full Name: glycine--tRNA ligase isoform 2
• NCBI Official Synonym Full Names: glycyl-tRNA synthetase
• NCBI Official Symbol: GARS
• NCBI Official Synonym Symbols: HMN5; CMT2D; DSMAV; GlyRS; SMAD1
• NCBI Protein Information: glycine--tRNA ligase
• UniProt Protein Name: Glycine--tRNA ligase
• Protein Family: Glycine--tRNA ligase
• UniProt Gene Name: GARS
• UniProt Synonym Gene Names: AP-4-A synthetase; GlyRS
• UniProt Entry Name: SYG_HUMAN

NCBI Description

This gene encodes glycyl-tRNA synthetase, one of the aminoacyl-tRNA synthetases that charge tRNAs with their cognate amino acids. The encoded enzyme is an (alpha)2 dimer which belongs to the class II family of tRNA synthetases. It has been shown to be a target of autoantibodies in the human autoimmune diseases, polymyositis or dermatomyositis. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2015]

Uniprot Description

GARS: Catalyzes the attachment of glycine to tRNA(Gly). Is also able produce diadenosine tetraphosphate (Ap4A), a universal pleiotropic signaling molecule needed for cell regulation pathways, by direct condensation of 2 ATPs. Defects in GARS are the cause of Charcot-Marie-Tooth disease type 2D (CMT2D). CMT2D is a form of Charcot- Marie-Tooth disease, the most common inherited disorder of the peripheral nervous system. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathy or CMT1, and primary peripheral axonal neuropathy or CMT2. Neuropathies of the CMT2 group are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. CMT2D is characterized by a more severe phenotype in the upper extremities (severe weakness and atrophy, absence of tendon reflexes) than in the lower limbs. CMT2D inheritance is autosomal dominant. Defects in GARS are a cause of distal hereditary motor neuronopathy type 5A (HMN5A); also known as distal hereditary motor neuropathy type V (DSMAV). A disorder characterized by distal muscular atrophy mainly affecting the upper extremities, in contrast to other distal motor neuronopathies. These constitute a heterogeneous group of neuromuscular diseases caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The overall clinical picture consists of a classical distal muscular atrophy syndrome in the legs without clinical sensory loss. The disease starts with weakness and wasting of distal muscles of the anterior tibial and peroneal compartments of the legs. Later on, weakness and atrophy may expand to the proximal muscles of the lower limbs and/or to the distal upper limbs. Belongs to the class-II aminoacyl-tRNA synthetase family.

Protein type: Mitochondrial; Translation; Ligase; EC 6.1.1.14

Chromosomal Location of Human Ortholog: 7p15

Cellular Component: axon; cytoplasm; cytosol; mitochondrial matrix; nucleoplasm; secretory granule

Molecular Function: ATP binding; glycine-tRNA ligase activity; protein dimerization activity

Biological Process: diadenosine tetraphosphate biosynthetic process; gene expression; glycyl-tRNA aminoacylation; tRNA aminoacylation for protein translation

Disease: Charcot-marie-tooth Disease, Axonal, Type 2d; Neuronopathy, Distal Hereditary Motor, Type Va